Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 2
2021 3
2022 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, Toi M, Imoto S, Jinno H. Yotsumoto D, et al. Breast Cancer. 2022 Jan;29(1):1-8. doi: 10.1007/s12282-021-01307-z. Epub 2021 Oct 19. Breast Cancer. 2022. PMID: 34665435
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, Matsui A, Miyazaki C, Shien T, Tokunaga E, Hayashi T, Niikura N, Maeda S, Komoike Y, Bando H, Kanbayashi C, Iwata H. Tanaka K, et al. Breast Cancer. 2021 Jul;28(4):896-903. doi: 10.1007/s12282-021-01225-0. Epub 2021 Feb 18. Breast Cancer. 2021. PMID: 33599914 Free PMC article.
5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).
Mitsunaga S, Ikeda M, Nomura S, Morizane C, Todaka A, Yamamoto N, Kamata K, Yanagibashi H, Mizuno N, Kawamoto Y, Gotoh K, Shirakawa H, Okano N, Nomura T, Tanaka K, Takahashi A, Yagi S, Ohta K, Takayama Y, Miwa H, Nagano H, Kojima Y, Hisano T, Tahara M, Sakuma Y, Arai H, Nakamura I, Katayama H, Konishi M, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG‐HBPOG). Mitsunaga S, et al. J Hepatobiliary Pancreat Sci. 2024 Sep 25. doi: 10.1002/jhbp.12071. Online ahead of print. J Hepatobiliary Pancreat Sci. 2024. PMID: 39318258